HK Stock Market Move | JW THERAP-B (02126) increases by nearly 10% CAR-T products approved for listing in Macau expected to drive sales revenue growth.

JW THERAP-B (02126) has risen by nearly 10%, reaching a 7.3% increase as of the time of publication, at 2.5 Hong Kong dollars, with a trading volume of 8,764,400 Hong Kong dollars. On the news front, on June 4th, Jingliuhengnuo announced that its independently developed CAR-T cell immunotherapy product targeting CD19, Ruijiaolunsa injectable solution, has received approval for a new drug application (NDA) from the Macao Food and Drug Administration in China. The company had also previously announced at the end of last month that the National Medical Products Administration had accepted a new indication for Ruijiaolunsa injectable solution for the second-line treatment of relapsed or refractory adult large B-cell lymphoma (r/r LBCL) patients. The company had previously stated that in the second half of 2024, the company's commercial team had undergone adjustments in terms of personnel and structure. A strong commercial team has been established, responsible for commercializing Ruijiaolunsa in China. The commercial team possesses strong commercialization capabilities, including sales teams, marketing teams, market access and innovation payment teams, and CAR-T advisory teams. The company expects that the sales revenue of Ruijiaolunsa will increase again in the next period. Ruijiaolunsa has outstanding product characteristics that can bring patients breakthrough value, and more indications are expected to be approved.